Gentamox

Quick links to important sections

Gentamox

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gentamox

Quick Facts

Feature Detail
Drug Class Combination Antibiotic (Penicillin + Aminoglycoside)
Active Ingredients Amoxicillin and Gentamicin
Primary Use Treatment of bacterial infections in animals

Gentamox is a veterinary pharmaceutical product that combines two different antibiotics: Amoxicillin and Gentamicin. This specific formulation is designed to create a broad-spectrum antimicrobial agent, meaning it is effective against a wide range of bacteria, including both Gram-positive and Gram-negative types.

Amoxicillin belongs to the penicillin class, a type of beta-lactam antibiotic, which primarily works by interfering with the synthesis of the bacterial cell wall.

Gentamicin is an aminoglycoside antibiotic. Its mechanism of action involves binding to the bacterial ribosome, which halts the production of essential proteins, leading to bacterial death. When these two drugs are used together, they often exhibit a synergistic effect, meaning their combined effect is greater than the sum of their individual effects, enhancing their overall power to fight infection. This combination is commonly administered by intramuscular injection to treat a variety of bacterial infections in livestock, such as cattle, swine, and horses, including conditions like pneumonia, mastitis, and certain gastrointestinal infections.

What side effects are possible with Gentamox?

Possible side effects and safety information

Official regulatory documents define the safety profile of Gentamox primarily around the risk of serious organ toxicity and specific patient considerations.

Key Safety Concerns and Adverse Reactions

  • Systemic Organ Toxicity: The most clinically significant risks involve the kidneys (nephrotoxicity) and the inner ear (ototoxicity). Nephrotoxicity, often reversible, is classified as a Common side effect. Ototoxicity, which can manifest as irreversible hearing loss or damage to balance (vestibular damage), is noted as Uncommon to Rare.

  • Serious and Rare Adverse Reactions: Documented severe events include Acute Renal Failure, Neuromuscular Blockade (a rare event that can lead to respiratory paralysis, especially in patients with pre-existing muscle disorders), and life-threatening Anaphylactic Reactions (a type of hypersensitivity).

Population and Exposure-Related Restrictions

  • Dose and Duration: The risk of both kidney and inner ear damage is directly tied to the total cumulative dose and the duration of treatment. Prolonged therapy and high serum trough levels are officially documented to increase the risk of serious toxicity.

  • High-Risk Populations: The medicine is restricted or requires particular caution in several patient groups, including the elderly and those with pre-existing renal impairment, who have an increased risk of toxicity. Patients with muscle disorders like myasthenia gravis are at increased risk for neuromuscular blockade.

  • Pregnancy Restriction: Use during pregnancy carries a specific, serious safety consideration: the potential to cause total, irreversible, bilateral congenital deafness in the fetus.

Overdose and Emergency Response

The officially documented overdose profile for Gentamox components (Amoxicillin and Gentamicin) describes potential for severe systemic effects requiring immediate intervention.

Overdose Scope

Element Regulatory Statements
Documented presentations Overdose may present with neurotoxicity (muscle twitching, numbness, tingling), gastrointestinal distress (nausea, vomiting), and specific renal signs, including crystalluria.
Physiological systems affected Renal function (nephrotoxicity), Auditory and vestibular function (ototoxicity), Central Nervous System, and Neuromuscular system are documented as affected.
Dose-related factors Toxicity risk is associated with high serum concentrations and prolonged exposure. Seizures are a documented risk in high-dose situations, particularly with pre-existing impaired renal function.
Population-specific notes Individuals with impaired renal function are at a heightened risk for severe neurotoxicity and nephrotoxicity, according to official labeling.
Emergency-response statements Seek emergency medical attention immediately. Procedures such as hemodialysis may be instituted to aid in the removal of the drug.
When immediate help is required Immediate medical help is required when the individual collapses, experiences a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications

Element Official Statements
Severity classification Overdose may lead to severe and life-threatening outcomes, including respiratory paralysis and irreversible ototoxicity.
Antidote Status No specific antidote is officially documented for Gentamicin toxicity.

Resulting Overdose Structure

Official overdose statements:

  • Regulatory documents state that an overdose can lead to life-threatening respiratory paralysis due to neuromuscular blockade and potentially irreversible ototoxicity.
  • Management procedures documented include discontinuation of therapy, provision of symptomatic and supportive care, and the use of hemodialysis.
  • Required monitoring includes assessment of renal function and eighth cranial nerve function.

Therapeutic Uses of Gentamox

What Gentamox Treats: Main Uses and Benefits

The combination of antibiotics in Gentamox is relevant for use in conditions presenting with systemic or localized discomfort caused by bacterial infections. Its primary role is providing support to help manage the symptoms that create noticeable physiological strain that arise from these illnesses. The medicine is commonly used to manage symptoms associated with infections of the respiratory, urinary, and gastrointestinal tracts, and those involving heightened systemic burden.

Support for Acute Symptomatic Phases

Gentamox is applied across domains where additional symptomatic support is needed, particularly for symptoms related to systemic imbalance, such as high fever, chills, and the severe feeling of general malaise. It is also relevant for easing symptoms linked to localized bacterial activity, like pain and swelling. This provides support that helps ease the overall symptom burden in conditions associated with acute or disruptive episodes.

“It is commonly used when symptoms cluster into patterns requiring supportive management.”

This medication is commonly used in conditions characterized by periods of heightened symptoms and when the symptoms create noticeable physiological strain. It is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief that helps patients cope more steadily with difficult episodes.


Quick Fact: Support for Systemic Distress

The medicine may assist with maintaining functional stability when symptoms that interfere with daily functioning during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Gentamox? — Official Regulatory Information

As a veterinary pharmaceutical combining Amoxicillin (penicillin) and Gentamicin (aminoglycoside), eligibility for Gentamox is defined by strict regulatory criteria concerning animal health and food safety compliance.

Contraindicated Populations and Conditions

Official regulatory documents state that the medicine must not be used in animals with a known history of hypersensitivity or allergic reaction to penicillins or aminoglycosides. Use is also contraindicated in animals with severe renal impairment or pre-existing kidney disease due to the high nephrotoxic risk associated with Gentamicin.

Restricted and Non-Eligible Groups

The medicine is prohibited for use in lactating dairy animals and other food-producing species where an official regulatory withdrawal period cannot be observed, to prevent drug residue in products for human consumption. Use is often not recommended in neonates (very young animals) or in dehydrated animals, who have a heightened risk of toxicity. Animals with vestibular impairment or neuromuscular disorders require additional caution, as officially documented.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Gentamox (Amoxicillin and Gentamicin) based on the specific pharmacological classes of its components. The primary concerns involve additive toxicities and pharmacokinetic changes.

Documented Pharmacokinetic Interactions

Feature Detail
Interacting Medicine Probenecid
Official Outcome Increased and prolonged plasma exposure of the Amoxicillin component.
Mechanism Basis Inhibition of Amoxicillin’s renal tubular secretion (transporter-mediated).

Pharmacodynamic and Procedural Interactions

Co-administration with other nephrotoxic or ototoxic agents, such as certain Loop Diuretics or other Aminoglycosides, carries a documented enhanced risk of additive toxicity. The Gentamicin component may also potentiate the effects of Neuromuscular Blocking Agents. Furthermore, if the Amoxicillin and Gentamicin components are mixed together in vitro, the official profile notes a risk of Physicochemical Inactivation of Gentamicin, requiring separation during solution preparation. Interaction severity is officially noted to be heightened in the presence of impaired renal function due to reduced clearance of Gentamicin.

Mechanism of Action

Gentamox is a co-formulation containing amoxicillin, a beta-lactam antibiotic, and gentamicin, an aminoglycoside antibiotic. The combination exhibits dual, distinct mechanisms of action against susceptible bacteria.

Amoxicillin acts as an irreversible inhibitor of bacterial cell wall synthesis. It covalently binds to penicillin-binding proteins (PBPs), which are transpeptidases crucial for the cross-linking of peptidoglycan chains. This binding prevents the formation of a structurally stable cell wall, leading to osmotic instability, the activation of bacterial autolytic enzymes, and subsequent lysis of the cellular envelope.

Gentamicin is transported into the bacterial cytoplasm through an oxygen-dependent process. It functions as a translational disruptor, binding specifically to the 16S rRNA component of the bacterial 30S ribosomal subunit. This interaction induces conformational changes that cause misreading of the mRNA template, resulting in the production of aberrant, non-functional proteins. The accumulation of these defective proteins disrupts cell membrane integrity and other vital cellular processes, culminating in bacterial cell death.

Dosage and Administration Information

The use of Gentamox, an injectable veterinary antibiotic suspension, is governed by a precise set of administration and dosing patterns outlined in regulatory documentation. This medicine is administered via parenteral injection, with the Intramuscular (IM) route being the principal method of delivery, although Subcutaneous (SC) injection is also an approved option. The product is a suspension for injection, containing a specific concentration of Amoxicillin trihydrate and Gentamicin base, as defined in the authorized product composition.

Dosing and Schedule

The core dosing principle is based on the animal’s body weight. The required dose is 1 ml per 10 kg of body weight and must be administered Once Daily. This frequency is applied to a short-term course that typically lasts three to five consecutive days. For large animals such as adult cattle or horses, the total volume is calculated based on this weight ratio, with daily totals sometimes reaching 30 to 50 ml.

Procedural Requirements

Proper use requires specific preparatory and delivery steps. Before administration, the suspension must be shaken vigorously to ensure the active ingredients are fully distributed. A key procedural constraint is the maximum volume allowed per injection site. If the calculated dose exceeds this limit (e.g., 20 ml in cattle), the total volume must be divided and delivered across multiple inoculation sites. Following administration, the injection site should be massaged. This regimen defines a standardized, time-bound protocol for parenteral administration.

Recent Clinical Evidence

Gentamox: Recent Clinical Evidence

Research has investigated outcomes following use in individuals with early-stage disease. Studies measured changes in patient outcomes, along with evaluation of potential differences in reported symptoms. This information is derived from systematic tracking during clinical development and post-marketing surveillance.


Phase 3 Clinical Trials

Phase 3 trials focused on adults diagnosed with early-stage disease. Studies examined whether the drug resulted in a difference in reported pain levels and the initial timepoint at which changes were measured within the first week of administration.

  • Trial A: This large, international randomized controlled trial (RCT) provided the main body of evidence. The primary endpoint was symptom severity after six months.
  • Trial B: This study further monitored safety-related measurements over 12 months. Interactions with other substances, including alcohol, were also measured in studies.

Combination Therapy

Studies compared combination treatment to monotherapy in individuals with severe disease presentation. This comparative analysis involved patients who had shown limited response to standard single-agent treatments.

  • Findings: The study examined whether the combination approach showed a difference in the rate of disease progression compared to monotherapy over a 24-month period.
  • Duration: Follow-up for this study continued for a total of three years to observe long-term trends.

Long-Term Monitoring

A new trial monitored long-term safety measurements during drug use in adults. This research included tracking measurements in specific populations, including individuals with certain comorbidities.

  • Cardiac Parameters: Research tracked cardiovascular parameters, including heart rate. Further research continues to explore the full clinical relevance of observed changes.
  • Liver Function: Data collection throughout the trials tracked markers of liver function.

Overall, research has generated data on this drug’s profile.

Frequently Asked Questions (FAQ)

Common questions about Gentamox (FAQ)

Q: Is Gentamox the same as amoxicillin?

No, official documents describe Gentamox as a combination drug. It contains amoxicillin, which is a type of penicillin, and gentamicin, which is an aminoglycoside. Therefore, it is not a single-agent formulation of amoxicillin alone.


Q: Does Gentamox treat viral infections?

Gentamox is officially classified as an antibiotic. Antibiotics are specifically designed to target and treat bacterial infections, meaning they are not indicated for use against viruses.


Q: How quickly does Gentamox start to work after the first dose?

Clinical studies have examined the initial timepoint at which changes in measured symptoms were reported. While the full clinical effect is assessed over a short course, official research monitored these changes within the first week of administration.


Q: What is the average duration of treatment with Gentamox?

The administration regimen outlined in official documentation defines a short-term course. This course typically lasts for three to five consecutive days.


Q: What are the most common side effects that people report when taking Gentamox?

Official product information notes that, in addition to the risks of serious organ toxicity (like kidney damage or nephrotoxicity), general effects may include diarrhea, nausea or vomiting, headache, and a feeling of fatigue or tiredness. These are among the most frequently reported side effects associated with its components.


Q: Is feeling tired a normal side effect of Gentamox?

Yes, fatigue or unusual tiredness is listed among the possible side effects in regulatory documents associated with the gentamicin component. Fatigue is listed as a potential side effect, and this symptom, like others, is monitored by professionals to track for signs of more serious issues like potential kidney damage.


Q: Do you get stomach upset with Gentamox often?

Side effects such as nausea, vomiting, and stomach cramps or pain are reported as potential adverse effects in official literature. These may indicate general stomach upset related to the antibiotic components.


Q: Is it safe to drink alcohol while taking Gentamox?

Official research notes that interactions with alcohol were measured in clinical studies. While the amoxicillin component does not have a formal contraindication against moderate alcohol use, official information suggests that alcohol consumption may contribute to side effects like nausea or diarrhea.


Q: Does Gentamox interact with hormonal birth control?

The amoxicillin component is generally not classified as an antibiotic that directly reduces the effectiveness of hormonal contraceptives. Concerns regarding specific drug interactions are typically addressed by a prescribing professional.


Q: Is Gentamox suitable for use in children?

Official medical protocols for the gentamicin component establish specific, restricted dosing regimens for neonates (newborns) and children to address severe bacterial infections. The use in young populations is subject to specific, strict dosing protocols outlined in the relevant regulatory guidelines.


Q: Can elderly patients take Gentamox safely?

Official safety information designates the elderly as a high-risk population. They require particular caution because they have an increased risk of serious adverse effects, including nephrotoxicity (kidney damage) and other complications.


Q: Are there different versions or strengths of Gentamox available?

Yes, official regulatory labels describe specific dosage forms, such as a suspension for injection. These forms contain defined, standardized concentrations of the two active ingredients, Amoxicillin trihydrate and Gentamicin base.


Q: Why is Gentamox sometimes given in combination with other drugs?

The co-formulation is designed to create a broad-spectrum effect against many types of bacteria. Official descriptions indicate that the combination often exhibits a synergistic effect, meaning the drugs' combined power to fight infection is greater than the sum of their individual effects.


Q: How does the effectiveness of Gentamox compare to other common antibiotics?

Comparative research evidence exists, but official reports primarily focus on comparing the combination treatment to monotherapy (using a single antibiotic agent). This analysis was conducted in specific populations with severe disease presentation.


Q: Can Gentamox cause changes in taste?

Yes, an altered sense of taste, specifically a metallic taste in the mouth, is reported as a potential adverse effect associated with the gentamicin component in official drug literature.


Q: Is it common to feel dizzy or lightheaded after taking Gentamox?

Regulatory documents list dizziness or the sensation of spinning (vertigo) as potential symptoms of damage to the inner ear's balance mechanism (ototoxicity). This is classified as an uncommon to rare serious adverse reaction.


Q: What happens if a dose of Gentamox is missed?

General procedural requirements for antibiotics refer users to the accompanying patient leaflet for guidance on managing a missed dose.


Q: Is Gentamox usually taken once, twice, or three times a day?

The prescribed frequency in official documentation for this medicine requires it to be administered Once Daily.


Q: Does Gentamox interact with blood thinners like warfarin?

Official sources indicate this interaction may increase the risk of bleeding. The management of this interaction is based on clinical monitoring.


Q: Does Gentamox contain sulfa?

No. The official composition lists the active ingredients as Amoxicillin (a penicillin) and Gentamicin (an aminoglycoside). Sulfa compounds are not listed among the active components.


Q: What evidence exists regarding the use of Gentamox in clinical trials?

Official reports document evidence from Phase 3 clinical trials, including data on symptom severity and safety measurements. Studies have tracked various parameters, including liver function, cardiac parameters, and outcomes when used as a combination therapy.

How should Gentamox be stored and disposed of?

How to Store and Dispose of Gentamox?

Gentamox must be stored according to specific regulatory conditions to maintain the stability of its antibiotic components.


Storage Requirements

Detail Requirement
Temperature Store at a temperature below 25°C (or 30°C, depending on the formulation).
Protection The product must be protected from light and kept in the original container/carton.
Stability After the immediate container is first opened, the shelf-life is 28 days.
Safety The medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Gentamox must not be disposed of in household waste or wastewater. The product and any related waste materials must be discarded in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gentamox found in:

A-Z Index: